A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

This publication has 31 references indexed in Scilit:

• Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
  New England Journal of Medicine, 2004
• Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study
  Alimentary Pharmacology & Therapeutics, 2003
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  Published by Elsevier ,2002
• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.
  Gut, 1993
• Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease
  Clinical and Experimental Immunology, 1993
• Evaluation of Different Laboratory Tests and Activity Indices Reflecting the Inflammatory Activity of Crohn's Disease
  Scandinavian Journal of Gastroenterology, 1992
• Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.
  Gut, 1991
• Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis
  European Journal of Clinical Investigation, 1982